chrysosplenol C: isolated from Pterocaulon sphacelatum; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
chrysosplenol C : A trimethoxyflavone that is the 3,7,3'-trimethyl ether derivative of quercetagetin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Pterocaulon | genus | [no description available] | Asteraceae | A large plant family of the order Asterales, subclass Asteridae, class Magnoliopsida. The family is also known as Compositae. Flower petals are joined near the base and stamens alternate with the corolla lobes. The common name of daisy refers to several genera of this family including Aster; CHRYSANTHEMUM; RUDBECKIA; TANACETUM.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 189065 |
| CHEMBL ID | 483031 |
| CHEBI ID | 3690 |
| SCHEMBL ID | 4742072 |
| MeSH ID | M0357752 |
| Synonym |
|---|
| 5,6-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-3,7-dimethoxy-4h-chromen-4-one |
| 23370-16-3 |
| quercetagetin 3,7,3'-trimethyl ether |
| chrysosplenol c |
| 3,7,3'-trimethylquercetagetin |
| 3, 7, 3'-o-trimethylquercetagetin |
| CHEMBL483031 |
| chebi:3690 , |
| LMPK12112982 |
| 5,6-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-3,7-dimethoxychromen-4-one |
| SCHEMBL4742072 |
| 5,6-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-3,7-dimethoxy-4h-1-benzopyran-4-one |
| 4',5,6-trihydroxy-3,3',7-trimethoxyflavone |
| DTXSID00177923 |
| 5,6,4'-trihydroxy-3,7,3'-trimethoxyflavone |
| AKOS030553631 |
| Q27106166 |
| chrysosplenol |
| 4h-1-benzopyran-4-one, 5,6-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-3,7-dimethoxy- |
| Excerpt | Reference | Relevance |
|---|---|---|
| "Chrysosplenol C was found to increase cell shortenings in a dose-dependent manner with a half-maximal effective concentration of 45 ± 7.8 μM." | ( Chrysosplenol C increases contraction in rat ventricular myocytes. Cuong, NM; Huong, do TT; Kim, HK; Kim, YH; Son, MJ; Van Sung, T; Woo, SH, 2011) | 2.53 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "We investigated how to overcome problems associated with the solubility, dissolution, and oral bioavailability of the poorly water-soluble drug compound, chrysosplenol C (CRSP), as well as the effects of single and binary hydrophilic polymers (PVP K-25 and/or PEG 6000) on the solubility and dissolution parameters of CRSP." | ( Solubilization and formulation of chrysosplenol C in solid dispersion with hydrophilic carriers. Choi, JS; Jang, WS; Kim, JK; Kim, TH; Kim, YH; Lee, JK; Lee, SE; Ng, CL; Park, JS, 2016) | 0.91 |
| Role | Description |
|---|---|
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| antiviral agent | A substance that destroys or inhibits replication of viruses. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| trihydroxyflavone | Any hydroxyflavone carrying three hydroxy groups at unspecified positions. |
| trimethoxyflavone | A methoxyflavone that is flavone substituted by three methoxy groups. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1892316 | Inhibition of ERK activity in human MM121224 cells harboring BRAF V600E/NRAS Q61K mutant derived from melanoma patient by high-content screening microscopic analysis | 2022 | Journal of natural products, 06-24, Volume: 85, Issue:6 | Combining Activity Profiling with Advanced Annotation to Accelerate the Discovery of Natural Products Targeting Oncogenic Signaling in Melanoma. |
| AID1242377 | Positive inotropic effect in Sprague-Dawley rat ventricular myocytes assessed as change in ventricular cell contractility at 10 uM by video edge detector relative to control | 2015 | ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7 | Exploration of Pharmacophore in Chrysosplenol C as Activator in Ventricular Myocyte Contraction. |
| AID1242383 | Activation of skeletal myosin S1 ATPase in rabbit psoas muscle at 10 uM in presence of actin thin filament complex | 2015 | ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7 | Exploration of Pharmacophore in Chrysosplenol C as Activator in Ventricular Myocyte Contraction. |
| AID1242382 | Solubility of the compound in DMSO/tyrode solution | 2015 | ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7 | Exploration of Pharmacophore in Chrysosplenol C as Activator in Ventricular Myocyte Contraction. |
| AID337762 | Cytotoxicity against human KB cells after 72 hrs | |||
| AID1242378 | Positive inotropic effect in Sprague-Dawley rat ventricular myocytes assessed as change in ventricular cell contractility at 50 uM by video edge detector relative to control | 2015 | ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7 | Exploration of Pharmacophore in Chrysosplenol C as Activator in Ventricular Myocyte Contraction. |
| AID1243246 | Cytotoxicity against mouse RAW264.7 cells assessed as reduction in cell viability at 10 to 40 uM by MTT assay | 2015 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18 | Chemical constituents of Miliusa balansae leaves and inhibition of nitric oxide production in lipopolysaccharide-induced RAW 264.7 cells. |
| AID1243248 | Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production at 20 uM by Griess reaction based ELISA method | 2015 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18 | Chemical constituents of Miliusa balansae leaves and inhibition of nitric oxide production in lipopolysaccharide-induced RAW 264.7 cells. |
| AID1892315 | Inhibition of AKT activity in human MM121224 cells harboring BRAF V600E/NRAS Q61K mutant derived from melanoma patient by high-content screening microscopic analysis | 2022 | Journal of natural products, 06-24, Volume: 85, Issue:6 | Combining Activity Profiling with Advanced Annotation to Accelerate the Discovery of Natural Products Targeting Oncogenic Signaling in Melanoma. |
| AID1242384 | Activation of smooth myosin S1 ATPase in chicken gizzard at 10 uM in presence of actin thin filament complex | 2015 | ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7 | Exploration of Pharmacophore in Chrysosplenol C as Activator in Ventricular Myocyte Contraction. |
| AID1243249 | Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production at 40 uM by Griess reaction based ELISA method | 2015 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18 | Chemical constituents of Miliusa balansae leaves and inhibition of nitric oxide production in lipopolysaccharide-induced RAW 264.7 cells. |
| AID1242381 | Activation of cardiac myosin S1 ATPase in bovine sarcomere at 10 uM by spectrophometric analysis in presence of actin thin filament complex relative to control | 2015 | ACS medicinal chemistry letters, Jul-09, Volume: 6, Issue:7 | Exploration of Pharmacophore in Chrysosplenol C as Activator in Ventricular Myocyte Contraction. |
| AID1243247 | Anti-inflammatory activity in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of nitric oxide production at 10 uM by Griess reaction based ELISA method | 2015 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18 | Chemical constituents of Miliusa balansae leaves and inhibition of nitric oxide production in lipopolysaccharide-induced RAW 264.7 cells. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.92) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (87.50%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||